EN DE
Watch KoBioLabs Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

KoBioLabs Inc (348150) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of KoBioLabs Inc stock KRW 2,223, price KRW 2,620, that is 15.1% below the price, quality 41 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

KI KoBioLabs Inc logo Thin data Nov 10, 2026

KoBioLabs Inc

348150 · KQ
Expensive, weak quality

Our calculation puts a fair price 15% below what the stock costs today.

Low debt
Ranks above peers (7/10)
Revenue last quarter +24% vs. a year ago.
Quality 41/100
Expensive Growth (revenue 5y +72.1 %/yr in KRW)
Fair value 2,223 KRW · Overvalued
Loss-making · -6.4% net margin (TTM)
Negative free cash flow
Narrow moat 12/100
Thin data
Estimate
Watch KoBioLabs Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

36,300 KRW 2,535 KRW Fair Value 2,223 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 2,535 KRW – 36,300 KRW · fair‑value band 1,667 KRW – 2,779 KRW · the 2,620 KRW price screens above the 2,223 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow KoBioLabs in your weekly email

Every Wednesday you see whether KoBioLabs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and brain diseases. The company was founded in 2014 and is based in Seoul, South Korea.

Stock analysis

KoBioLabs Inc (348150) currently trades at 2,620 KRW, while our estimate is 2,223 KRW, 15% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,667 KRW (bear) to 2,779 KRW (bull), the price of 2,620 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

KoBioLabs Inc reported revenue of 69.3B KRW in FY2025 versus 2.9B KRW in FY2021, a compound +121.2%/yr. Reported net income was −6.3B KRW in FY2025.

Key figures

Market cap 50.9B KRW (≈ $38.2M) Micro · P/S ratio 0.69 · EPS (TTM) −247.39 KRW · Net margin −6.4% · Return on equity −10.0% · Return on assets (EBIT) −13.0% (5-year average) · Operating margin −9.2% · Revenue (TTM) 75.4B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 61% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −15%, 348150 screens richer than that median.

Fair Value

Bear 1,667 KRW Fair Value 2,223 KRW Bull 2,779 KRW
Price 2,620 KRW · Downside -15.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 36
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 54
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+81.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.1%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+171.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−268.7% (2020) → −13.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

348150 screens overvalued: fair value 15% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare KoBioLabs Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 41 · Above median
Fair Value upside −15.1% · Above median
Profitability
Return on assets −6.9% · Above median
Net margin (12 months) −6.4% · Below median
Operating margin (12 months) −9.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) 23.8% · Above median
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.57× · Cheaper than median
P/S (12 months) 0.68× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)13 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)90 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 348150
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 348150
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 348150
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 348150
argenx SE ARGX $971.55 $908.40 −7% vs 348150
CSL Limited CSL A$201.68 A$181.40 −10% vs 348150
Moderna, Inc MRNA $250.83 $158.70 −37% vs 348150
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 348150
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 348150
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 348150

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

KoBioLabs Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "KoBioLabs Inc Fair Value". https://www.fairvalue-calculator.com/stock/348150

Frequently asked questions

Is KoBioLabs Inc (348150) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 2,223 KRW versus a price of 2,620 KRW, about 15% lower (overvalued).
What is the fair value of 348150?
Our estimate for KoBioLabs Inc is 2,223 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 2,620 KRW.
What is the quality score of 348150?
KoBioLabs Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for KoBioLabs Inc (348150)?
Our calculated price target is the estimate of 2,223 KRW (as of Nov 10, 2026). Cautious scenario 1,667 KRW, optimistic scenario 2,779 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the KoBioLabs Inc stock forecast for 2026?
Our estimate puts fair value at 2,223 KRW, about 15% lower versus a price of 2,620 KRW (overvalued). Cautious scenario 1,667 KRW, optimistic scenario 2,779 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of KoBioLabs Inc (348150)?
KoBioLabs Inc reported trailing-twelve-month revenue of about 75.4B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of KoBioLabs Inc (348150)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For KoBioLabs Inc it is 2,223 KRW per share (as of Nov 10, 2026), against a price of 2,620 KRW.
Is KoBioLabs Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 348150 trades above its calculated fair value: price 2,620 KRW, fair value 2,223 KRW, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 348150?
No. The price is what the market pays today (2,620 KRW); the fair value is what the company's own numbers justify (2,223 KRW). For KoBioLabs Inc the two are 396.68 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is KoBioLabs Inc worth?
The market values KoBioLabs Inc at about 50.9B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 2,620 KRW; our models calculate a fair value of 2,223 KRW per share.
What do the bullish and bearish scenarios say about 348150?
Our models span a range for KoBioLabs Inc: cautious scenario 1,667 KRW, base 2,223 KRW, optimistic 2,779 KRW per share (as of Nov 10, 2026, price 2,620 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of KoBioLabs Inc (348150)?
Balance-sheet figures for KoBioLabs Inc (as of Nov 10, 2026): return on equity −10.0%, debt of 0.20 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 348150 from its 52-week high?
KoBioLabs Inc trades at 2,620 KRW, about 61% below its 52-week high of 6,720 KRW and 3% above the low of 2,535 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 2,223 KRW is for.
Which stocks are comparable to KoBioLabs Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is KoBioLabs Inc stock attractive at the current price?
The data as of Nov 10, 2026: price 2,620 KRW, calculated fair value 2,223 KRW (−15%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. KoBioLabs Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of KoBioLabs Inc (348150)?
The closing price on Nov 10, 2026 was 2,620 KRW. Our estimate is 2,223 KRW, about 15% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with KoBioLabs Inc right now?
Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of KoBioLabs Inc

How large is the market capitalisation of KoBioLabs Inc (348150)?
The market capitalisation of KoBioLabs Inc is 50.9B KRW (≈ $38.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of KoBioLabs Inc (348150)?
The price-to-sales ratio of KoBioLabs Inc is 0.69 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of KoBioLabs Inc (348150)?
Earnings per share at KoBioLabs Inc are −247.39 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of KoBioLabs Inc (348150)?
The net margin of KoBioLabs Inc is −6.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of KoBioLabs Inc (348150)?
The return on equity (ROE) of KoBioLabs Inc is −10.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of KoBioLabs Inc (348150)?
On an EBIT basis the return on assets of KoBioLabs Inc is −13.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of KoBioLabs Inc (348150)?
The operating margin of KoBioLabs Inc is −9.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at KoBioLabs Inc (348150)?
Revenue at KoBioLabs Inc is growing +23.8% versus a year earlier (3y avg +81.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does KoBioLabs Inc (348150) generate?
The free cash flow of KoBioLabs Inc is −6.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does KoBioLabs Inc (348150) carry?
The net debt of KoBioLabs Inc is 8.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch KoBioLabs Inc in the live analysis

One click puts KoBioLabs Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.